ArticleFrontiers in microbiology2023
A clinical analysis of
Article in Frontiers in microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.
- Candida tropicalis-A systematic review to inform the World Health Organization of a fungal priority pathogens list.Medical mycology · 2024Pooled it
- Population genomics reveals a long-term increase in azole resistance associated with the emerging cluster AZR amongEmerging microbes & infections · 2026Article
- Review
- Article
- Subtractive proteomics-assisted putative drug target and inhibitor identification: a study based on six Candida species.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Development and validation of a nomogram for early prognostic prediction in childhood aplastic anemia receiving cyclosporine monotherapy.Pediatric research · 2026Article
- From tradition to evidence: medicinal plants used for childhood diseases in the Ehlanzeni District, Mpumalanga Province, South Africa.Frontiers in pediatrics · 2026Review
- Article
- Genotypic Analysis of Candida tropicalis Clinical Isolates From Korea via Multilocus Sequence Typing.MicrobiologyOpen · 2025Article
- Optimization ofFrontiers in bioengineering and biotechnology · 2025Article
- Nineteen years retrospective analysis of epidemiology, antifungal resistance and a nomogram model for 30-day mortality in nosocomial candidemia patients.Frontiers in cellular and infection microbiology · 2025Article
- Antifungal susceptibility and virulence determinants profile of candida species isolated from patients with candidemia.Scientific reports · 2024Article
- Case report: Successful combination therapy with isavuconazole and amphotericin B in treatment of disseminatedFrontiers in medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Summary objective: To assess the clinical features and outcomes of hematological disease patients with Methods: This is a retrospective, single-center, observational study conducted in the Department of Hematology at The First Affiliated Hospital of Guangxi Medical University from January 2013 to December 2021. A total of 26 hematological disease patients with Results: The patients had a mean age of 35 years (range: 10-65 years), 50% were male (13/26) and 88.5% had hematologic malignancies (23/26) while the remaining three patients included two cases of severe aplastic anemia and one case of β-thalassemia. All patients had neutropenia. Seven patients were initially given azole alone (26.9%), five of whom failed treatment and died (71.4%). Fifteen patients were treated with echinocandin (57.7%), three of whom failed treatment and died (20.0%), and eight patients were treated with amphotericin B (30.8%), two of whom failed treatment and died (25.0%). The total and attributable mortality rates were 42.3 and 34.6%, respectively. Univariate analysis showed that there are six risk factors for attributable deaths among hematological disease patients with Conclusion: Hematological disease patients with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.